Published online before print June 9, 2003, doi: 10.1161/01.CIR.0000072771.11429.83
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2908.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Clopidogrel for Coronary Stenting
Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity
From the Sinai Center for Thrombosis Research (P.A.G., K.P.B., B.L.H.), Baltimore, Md, and Duke Clinical Research Institute (C.M.O.), Durham, NC.
Correspondence to Paul A. Gurbel, MD, Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215. E-mail pgurbel{at}lifebridgehealth.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Clopidogrel is administered to prevent stent thrombosis; however, the uniformity of platelet inhibition after treatment and the influence of pretreatment reactivity on drug response have not been described.
Methods and Results— Platelet aggregation (5 and 20 µmol/L ADP), the activation of glycoprotein IIb/IIIa (PAC-1 antibody), and the expression of P-selectin were measured in patients undergoing elective coronary stenting (n=96) at baseline and at 2 hours, 24 hours, 5 days, and 30 days after stenting. All patients received aspirin (325 mg). Clopidogrel (300 mg) was administered in the catheterization laboratory and followed by 75 mg daily. There was marked interindividual variability in drug response as measured by all markers that showed a normal distribution. Resistance, defined as baseline aggregation (%) minus posttreatment aggregation (%) ≤10% by 5 µmol/L ADP, was present in 31% and 15% of patients at 5 and 30 days, respectively. Patients with the highest pretreatment platelet reactivity remained the most reactive at 24 hours after treatment (P<0.0001).
Conclusions— Interindividual variability in the platelet inhibitory response from clopidogrel occurs in patients undergoing elective coronary stenting. Patients with high pretreatment reactivity are least protected. Alternative pharmacological strategies and the association of adverse ischemic events should be investigated in these patients.
Key Words: drugs • platelets • stents
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clopidogrel with aspirin is the regimen of choice to prevent stent thrombosis.1 The CURE study (Clopidogrel in Unstable angina to prevent Recurrent Events) showed that combination clopidogrel and aspirin antiplatelet therapy reduces ischemic events compared with aspirin therapy alone.2 These findings are consistent with those of the CAPRIE study (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events), which showed superior reduction in ischemic events with clopidogrel therapy compared with aspirin, and which may be explained in part by aspirin resistance.3 However, the uniformity of inhibition after clopidogrel therapy and the incidence of drug resistance has not been investigated extensively. Interindividual variability in response to clopidogrel may affect clinical outcomes.4
We studied the individual responses to clopidogrel therapy in patients undergoing elective coronary artery stenting by measuring platelet aggregation and other markers of platelet activation by flow cytometry for 30 days after the procedure.5 The frequency of drug resistance is reported. We also studied the influence of pretreatment platelet reactivity on drug response.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study was approved by the Investigational Review Board. Consecutive patients undergoing elective coronary stenting were enrolled after giving informed consent. All ages were included. The exclusion criteria were a history of bleeding diathesis, acute myocardial infarction within 48 hours, cerebrovascular event within 3 months, illicit drug or alcohol abuse, prothrombin time >1.5 times control, platelet count <100 000/mm3, hematocrit <25%, creatinine >4.0 mg/dL, and thienopyridine or glycoprotein (GP) IIb/IIIa use before the procedure.
Per protocol, GP IIb/IIIa inhibitors were not given. Clopidogrel (300 mg) was given to all patients in the catheterization laboratory after successful coronary artery stent implantation followed by 75 mg daily for 30 days. In addition, all patients had received at least 81 mg of aspirin for 7 days before the procedure (>90% received 325 mg) and were administered 325 mg on the day of the procedure and daily thereafter. Heparin to achieve an activated clotting time >300 seconds was administered as a bolus to all patients in the catheterization laboratory immediately before stenting.
Blood Sampling
Blood was collected in evacuated container tubes containing 3.8% trisodium citrate that were filled to capacity and then inverted 3 to 5 times for gentle mixing. Samples were obtained before clopidogrel administration (baseline) and at 2 hours, 24 hours, 5 days, and 30 days after stenting.
Platelet Aggregation
The blood-citrate mixture was centrifuged at 1200g for 2.5 minutes. The resulting platelet-rich plasma was kept at room temperature for use within 1 hour. The platelet count was determined in the platelet-rich plasma sample and adjusted to 3.5x108/mL with homologous platelet-poor plasma. Platelets were stimulated with ADP (5 and 20 µmol/L), and aggregation was assessed as described previously with a Chronolog Lumi-Aggregometer (model 560-Ca) with the AggroLink software package.6 Platelet aggregation was expressed as the maximal percent change in light transmittance from baseline, with platelet-poor plasma used as a reference. Curves were analyzed according to accepted standards.7
Flow Cytometry
The surface expression of platelet receptors was determined by flow cytometry with monoclonal antibodies. Briefly, the blood-citrate mixture (50 µL) was diluted with 450 µL of Tris buffered saline (10 mmol/L Tris, 0.15 mol/L sodium chloride) and mixed by inverting an Eppendorf tube gently 2 times. The corresponding antibody was then added (5 µL) and incubated at room temperature for 30 minutes. After incubation, 400 µL of 2% buffered paraformaldehyde was added for fixation. The samples were analyzed on a Becton Dickinson FACScan flow cytometer set up to measure fluorescent light scatter as described previously.8 All parameters were collected with four-decade logarithmic amplification. The data were collected in list-mode files and then analyzed. The PAC-1 antibody (Becton Dickinson) binds only to the active 
IIbß3 receptor, and therefore the total amount of IIbß3 is not determined.9 PAC-1 was expressed as log mean fluorescence intensity. P-selectin (Pharmingen) was measured after stimulation with 200 µmol/L ADP and is expressed as percent positivity (ie, the percentage of platelets positive for the antibody) as described previously.10 The dose of agonist was chosen on the basis of data reporting maximum expression of P-selectin induced by 100 µmol/L ADP in the absence of an ADP blocker.5
Drug Resistance Definition
Drug resistance was defined as an absolute difference between baseline aggregation and posttreatment aggregation (
aggregation [%]) of 10% or less with 5 µmol/L ADP used as the agonist. Because aggregation (%) = baseline aggregation (%) - posttreatment aggregation (%), a negative aggregation would indicate poststent platelet reactivity greater than baseline, and a positive aggregation would indicate platelet inhibition.
Statistical Analysis
The responders and nonresponders were compared with t tests. Standard regression analysis was used to correlate 5 and 20 µmol ADP/L-induced aggregation and 5- and 30-day aggregation and P-selectin expression (Statistica software).
To assess the effect of pretreatment reactivity on drug response, patients were divided into high, moderate, and low baseline reactivity.11 Two separate analyses were performed on the basis of aggregation and P-selectin expression. For 5 µmol/L ADP-induced aggregation, high reactivity was defined as percent aggregation >70%; moderate, 60% to 70%; and low, <60%. For P-selectin, high reactivity was defined as percent positivity >50%; moderate, 40% to 50%; and low, <40%. Comparisons were made between groups by 1-way ANOVA (Statistica software). The Wilks-Shapiro test was used to assess conformity with a normal distribution. Curves were plotted of the best fit to a normal distribution by Statistica software. Given the normal distribution of data, the mean±SD and mean±SE were used. P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient Data
Ninety-six patients had complete platelet studies performed at baseline, and of these patients, 92 had adequate poststent samples. The patient demographics on these 92 patients are shown with respect to the response to 5 µmol/L ADP-induced aggregation at day 5 in the Table. The patients were elderly, and most were males. Multiple cardiovascular risk factors were frequent. Concomitant drug use did not differ significantly between groups. A trend of higher calcium antagonist and ACE inhibitor use was observed in the nonresponders. Most patients were treated with 1 stent. There were no significant procedural differences between responders and nonresponders except for total stent length. Follow-up at 30 days revealed no cases of Q-wave myocardial infarction, stent thrombosis, target-vessel revascularization, cerebrovascular ischemic events, or death.
|
Platelet Aggregation
Histograms of the response to clopidogrel are shown in Figures 1 and 2 
. Baseline aggregation to 5 and 20 µmol/L ADP was 62±18% and 83±21%, respectively. The response to 5 and 20 µmol/L ADP showed a shift to the right between 2 and 24 hours after treatment, which indicates increased platelet inhibition. Aggregation by 5 µmol/L ADP was maximally inhibited by 24 hours (P<0.05 compared with baseline). Platelet aggregation was 58±22% at 2 hours, 37±22% at 24 hours, 32±18% at 5 days, and 31±15% at 30 days. At 2 hours after stenting, 63% of patients met the definition of resistance and platelet reactivity was greatest, with 42% of patients having greater aggregation than at baseline. At 24 hours, resistance fell to 31%, and 24% of patients still had greater aggregation than at baseline. No further changes were seen at 5 days, when resistance was observed in 31%. However, at 30 days after stenting, the incidence of resistance fell to 15%, but 11% still had aggregation greater than baseline.
|
|
The response to 20 µmol/L ADP showed a similar pattern. Aggregation was 80±24% at 2 hours and fell to 60±25% at 24 hours (P<0.05 compared with baseline). At 5 days, aggregation remained stable (57±23%), with a nonsignificant decrease at 30 days (52±14%). A aggregation of 10% or less was present in 53% of patients at 2 hours, 35% at 24 hours, 32% at 5 days, and 21% at 30 days. The correlation between the 5- and 20-µmol/L ADP aggregation response was strong (r=0.6).
Correlation of Responses at 5 and 30 Days
A strong correlation was observed between the 5- and 30-day responses to 5 µmol/L ADP (r=0.8). Moreover, strong correlations were also observed between 5- and 30-day responses for 20 µmol/L ADP (r=0.8) and P-selectin (r=0.7).
Platelet Receptor Expression
P-Selectin
Baseline stimulated P-selectin expression was 45±16% and fell over 24 hours, as indicated by a shift in the curve to the right (Figure 3). Maximum inhibition of P-selectin expression occurred within 24 hours (24±13%; P<0.05 compared with baseline) and was unchanged at 5 days (22±13%) and 30 days (23±10%), as observed in the aggregation studies. An absolute change in percent positivity of 10% or less was observed in 44% of patients at 2 hours, 25% at 24 hours, 12% at 5 days, and 29% at 30 days, which again suggests resistance to the standard clopidogrel regimen.
|
PAC-1
PAC-1 binding showed similar response variability (Figure 4). Baseline expression was 14.9±13.1, and inhibition of the expression of active GP IIb/IIIa was maximal within 24 hours (8.5±5.1; P<0.05 compared with baseline). No significant changes as compared with 24 hours were observed at 5 days (8.1±3.7) or 30 days (8.6±5.3).
|
Effect of Pretreatment Platelet Reactivity on Drug Response
High pretreatment reactivity, defined by the response to 5 µmol/L ADP, was present in 31 patients, moderate reactivity in 25 patients, and low reactivity in 40 patients. High-reactivity patients had a greater incidence of diabetes (71%; P<0.05) than those with moderate (24%) and low (40%) reactivity. Patient weight, gender, age, statin use, smoking history, incidence of hyperlipidemia, history of prior infarction, total contrast load, procedure duration, and number of vessels treated were not significantly different between groups.
Platelet Aggregation
At baseline, by definition, the high-reactivity group had markedly greater reactivity (78±6%) than the moderate (65±3%; P<0.00001) and low (48±9%; P<0.00001) groups (Figure 5A). At day 1 after stenting, the high-reactivity group continued to have the most reactive platelets (67±11%; P=0.004 versus moderate [56±15%] and P<0.0001 versus low [52±15%]). By day 5, platelet reactivity by this marker was similar among groups.
|
P-Selectin Expression
At baseline, the high-reactivity group had greater expression (67±7%) than the moderate (44±3%; P<0.00001) and low (29±6%; P<0.00001) groups (Figure 5B). The effect that pretreatment reactivity had on the inhibitory response to clopidogrel at day 1 was remarkably similar to findings with ADP-induced light-transmittance aggregometry. At day 1, patients with high pretreatment P-selectin expression remained the most reactive (P<0.001 versus low reactivity). At day 5 of therapy, patients in the high-reactivity group had a trend to greater P-selectin expression than the moderate (31±12% versus 19±13%; P=0.06) and low (20±7%; P=0.04) groups.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study illustrates the variable platelet inhibitory response to the standard administered dose of clopidogrel. The platelet aggregation studies used 2 agonist concentrations that showed a strong correlation. In addition, platelet receptor expression showed similar findings. These uniform observations, irrespective of the methodology chosen to detect inhibition, strengthen our conclusions that the response to clopidogrel therapy is indeed heterogeneous and that drug resistance occurs. Our observations are in agreement with one other report of 18 patients with stable angina treated with the same clopidogrel regimen after coronary intervention.12 Those investigators demonstrated variable inhibition of ADP-induced fibrinogen binding on day 2 after stenting.
Our definition of drug resistance was empirical because there have been no extensive reports on this subject among patients treated with clopidogrel. Clopidogrel inhibits aggregation in response to ADP, and therefore, we studied the response to 2 different concentrations of this agonist with light-transmittance aggregometry. Moreover, we assessed the expression of an established marker of platelet activation (P-selectin) in response to a maximal agonist concentration and studied the response of a sensitive platelet activation–dependent marker (PAC-1 binding) in nonstimulated blood.5,9
The present study suggests that the maximum inhibitory response to a 300-mg loading dose followed by 75 mg/d occurs within 24 hours. These findings are consistent with reports in healthy volunteers and in patients undergoing coronary stenting.13,14
The response to clopidogrel appears to be patient specific. The robust correlations demonstrated that in most patients, the 30-day inhibitory response from clopidogrel was predicted by the 5-day response. Of equal importance, the present investigation also suggests that resistance to clopidogrel does not accrue over time.
The present study is the first to demonstrate that the level of platelet reactivity after the standard clopidogrel regimen for coronary stenting is critically dependent on the pretreatment reactivity. The present in vitro tests suggest that patients with the greatest pretreatment platelet activity have the least antithrombotic protection, particularly within the first 24 hours of therapy. The level of platelet reactivity has been correlated with adverse events by others.4 Moreover, an examination of P-selectin expression suggests that this relationship is true even after 5 days of therapy, when those patients with the greatest baseline expression of this activation-dependent receptor tended to be more reactive than those with baseline low or moderate expression. The present findings may help to explain why ticlopidine without a loading dose did not prevent stent thrombosis in the first 3 days after the procedure.15 The similar findings at 24 hours using 2 different established markers of platelet activity strengthen our conclusion that the response to clopidogrel therapy is indeed dependent on pretreatment reactivity. Previous investigations using aggregometry and P-selectin expression as markers of reactivity have shown that loading doses higher than 300 mg may enhance and accelerate platelet inhibition in patients undergoing coronary interventions.16–19 Similar strategies may particularly benefit patients with high pretreatment reactivity.
Limitations
The present study included patients undergoing elective coronary stenting, which is known to increase platelet reactivity.8 Because pretreatment reactivity affected the reactivity measured after antiplatelet therapy, postdrug platelet reactivity may be less in studies of healthy volunteers and in patients with stable coronary artery disease. Our definition of resistance involves the amplitude of maximal platelet aggregation and can be influenced by various factors, including intrapatient variability. The current rates of stent thrombosis observed in elective stenting are much lower than the incidence of clopidogrel resistance in the present study, which suggests that our definition may be an overestimate or that resistance to clopidogrel is not a primary factor influencing stent thrombosis in these patients. However, the present data imply that nonresponders with high pretreatment reactivity may be at greatest risk.
In conclusion, the platelet inhibitory response to the standard dosing regimen of clopidogrel for coronary stenting is variable, follows a normal distribution, and appears stable over 30 days. Patients with high pretreatment reactivity are the least protected within the first 5 days of treatment. Further study is necessary to investigate the mechanisms of these findings and how they correlate with the occurrence of ischemic events. The present work would also support further investigations to determine whether higher clopidogrel doses may overcome interindividual differences in drug response.
|
Acknowledgments |
|---|
Supported by the Sinai Center for Thrombosis Research and Platelet and Thrombosis Research, LLC.
Received January 29, 2003; revision received March 20, 2003; accepted March 21, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Gurbel PA, O’Connor CM, Cummings CC, et al. Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Pharm Res. 1999; 65: 109–123.
2. Yusuf S, Zhao F, Mehta SR, et al, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329–1339.[CrossRef][Medline] [Order article via Infotrieve]
4. Steinhubl SR, Talley JD, Braden GA, et al. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001; 103: 2528–2530.
5. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987; 70: 307–315.
6. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 1998; 31: 1466–1473.
7. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31: 29–39.[Medline] [Order article via Infotrieve]
8. Gurbel PA, Cummings CC, Bell CR, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 2003; 145: 239–247.[CrossRef][Medline] [Order article via Infotrieve]
9. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999; 99: E1–E11.[Medline] [Order article via Infotrieve]
10. Gurbel PA, Kereiakes DJ, Dalesandro MR, et al. Role of soluble and platelet-bound p-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. Am Heart J. 2000; 139: 320–328.[Medline] [Order article via Infotrieve]
11. Serebruany VL, Gurbel PA, Shustov AR, et al. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. Am Heart J. 1998; 136: 398–405.[CrossRef][Medline] [Order article via Infotrieve]
12. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002; 252: 233–238.[CrossRef][Medline] [Order article via Infotrieve]
13. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999; 25: 15–19.[Medline] [Order article via Infotrieve]
14. Gurbel PA, Malinin AI, Callahan KP, et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol. 2002; 90: 312–315.[CrossRef][Medline] [Order article via Infotrieve]
15. Schuhlen H, Kastrati A, Dirschinger J, at al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998; 98: 104–111.
16. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002; 143: 118–123.[CrossRef][Medline] [Order article via Infotrieve]
17. Claeys MJ, Van Der Planken MG, Michiels JJ, et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis. 2002; 13: 283–288.[CrossRef][Medline] [Order article via Infotrieve]
18. Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol. 2001; 87: 332–336.[CrossRef][Medline] [Order article via Infotrieve]
19. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001; 85: 92–93.
This article has been cited by other articles:
 |
|
 |
|
  N. Chapman and M. Schachter Clopidogrel and calcium-channel blockers: a clinically important interaction? Heart, February 1, 2010; 96(3): 179 - 180. [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Farid, A. Kurihara, and S. A. Wrighton Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans J. Clin. Pharmacol., February 1, 2010; 50(2): 126 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, A. Kilias, B. Bigalke, K. Stellos, M. Schwab, A. E. May, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur. Heart J., January 1, 2010; 31(1): 59 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mangiacapra, B. De Bruyne, O. Muller, C. Trana, A. Ntalianis, J. Bartunek, G. Heyndrickx, G. Di Sciascio, W. Wijns, and E. Barbato High Residual Platelet Reactivity After Clopidogrel: Extent of Coronary Atherosclerosis and Periprocedural Myocardial Infarction in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., January 1, 2010; 3(1): 35 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berger, D. L. Bhatt, C. P. Cannon, Z. Chen, L. Jiang, J. B. Jones, S. R. Mehta, M. S. Sabatine, S. R. Steinhubl, E. J. Topol, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1935 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rudez, H. J. Bouman, J. W. van Werkum, F. W.G. Leebeek, A. Kruit, H. J.T. Ruven, J. M. ten Berg, M. P.M. de Maat, and C. M. Hackeng Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions Circ Cardiovasc Genet, October 1, 2009; 2(5): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol., September 8, 2009; 54(11): 969 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al. Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy JAMA, August 26, 2009; 302(8): 849 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Perez de Prado, C. Cuellas, A. Diego, A. de Miguel, and F. Fernandez-Vazquez Platelet reactivity and stent thrombosis: still some issues to solve. J. Am. Coll. Cardiol., August 11, 2009; 54(7): 666 - 667. [Full Text] [PDF]
|
|
|
|
|
|
L. Wallentin P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Verstuyft, T. Simon, and R. B. Kim Personalized medicine and antiplatelet therapy: ready for prime time? Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963. [Full Text] [PDF]
|
|
|
|
|
|
L Bonello, A De Labriolle, M Scheinowitz, G Lemesle, P Roy, D H Steinberg, T L Pinto Slottow, R Pakala, A D Pichard, P Barragan, et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines Heart, August 1, 2009; 95(15): 1214 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Adventures in Cardiovascular Research Circulation, July 14, 2009; 120(2): 170 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines Combining Antiplatelet and Anticoagulant Therapies. J. Am. Coll. Cardiol., July 7, 2009; 54(2): 95 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michelson, A. L. Frelinger III, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur. Heart J., July 2, 2009; 30(14): 1753 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D. J. Angiolillo, M. Sabate, M. Hamon, A. Repetto, et al. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study Circulation, June 30, 2009; 119(25): 3215 - 3222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad and D. R Holmes Update on dual antiplatelet therapy for percutaneous coronary intervention Heart, June 1, 2009; 95(11): 861 - 865. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. L. Macias, E. Braunwald, et al. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes Circulation, May 19, 2009; 119(19): 2553 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Ford Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic? J. Clin. Pharmacol., May 1, 2009; 49(5): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon, and M. S. Sabatine Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1273 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veverka and J. M. Hammer Prasugrel: A New Thienopyridine Inhibitor Journal of Pharmacy Practice, April 1, 2009; 22(2): 158 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 T. C. Collyer, D. J. Gray, R. Sandhu, J. Berridge, and G. Lyons Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography(R) Platelet MappingTM Br. J. Anaesth., April 1, 2009; 102(4): 492 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mahla, M. J. Antonino, U. S. Tantry, and P. A. Gurbel Point-of-care platelet function analysis ready for prime time? J. Am. Coll. Cardiol., March 10, 2009; 53(10): 857 - 859. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hopkins and M. Limacher The Role of Aspirin in Cardiovascular Disease Prevention in Women American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 123 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel N. Engl. J. Med., January 22, 2009; 360(4): 354 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. X. Zhao, M. Leacche, J. M. Balaguer, K. D. Boudoulas, J. A. Damp, J. P. Greelish, J. G. Byrne, and the Writing Group on behalf of the Cardiac Surgery Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J. Am. Coll. Cardiol., January 20, 2009; 53(3): 232 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kim, H. K. Lee, K. Han, and H.-K. Jeon Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary Artery Disease or Ischemic Cerebrovascular Disease Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1968 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Saw, E. H. Madsen, S. Chan, and E. Maurer-Spurej The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1826 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ang and E. Mahmud Monitoring oral antiplatelet therapy: is it justified? Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 485 - 496. [Abstract] [PDF]
|
|
|
|
|
|
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al. The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 612 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al. The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 620 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Kleiman Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 628 - 630. [Full Text] [PDF]
|
|
|
|
|
|
B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.-P. Collet, G. Montalescot, J.-P. Cazenave, M.-C. Dickele, J.-P. Monassier, and C. Gachet Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention: Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Velik-Salchner, S. Maier, P. Innerhofer, W. Streif, A. Klingler, C. Kolbitsch, and D. Fries Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study Anesth. Analg., December 1, 2008; 107(6): 1798 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Kleiman Clopidogrel and Calcium-Channel Antagonists: Another Drug-Drug Interaction for the Ever-Wary Clinician? J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1564 - 1566. [Full Text] [PDF]
|
|
|
|
|
|
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Williams and J. D. Abbott What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax? Circulation, September 16, 2008; 118(12): 1219 - 1222. [Full Text] [PDF]
|
|
|
|
|
|
K. P. Bliden, J. DiChiara, L. Lawal, A. Singla, M. J. Antonino, B. A. Baker, W. L. Bailey, U. S. Tantry, and P. A. Gurbel The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel J. Am. Coll. Cardiol., August 12, 2008; 52(7): 531 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.P.P. Peluso, W.J. van Rooij, M. Sluzewski, and G.N. Beute A New Self-Expandable Nitinol Stent for the Treatment of Wide-Neck Aneurysms: Initial Clinical Experience AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1405 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.H. Lee, A. Arat, H. Morsi, H. Shaltoni, J.R. Harris, and M.E. Mawad Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Price New antiplatelet therapies in development Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S11 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart, June 1, 2008; 94(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al. Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1925 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M.-C. Simeoni, P. Barragan, F. Dignat-George, and F. Paganelli Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1404 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Kleiman Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel? J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1412 - 1414. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J., April 2, 2008; 29(8): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr Resistance to what, does it matter? How do we study it? Eur. Heart J., April 2, 2008; 29(8): 957 - 958. [Full Text] [PDF]
|
|
|
|
|
|
S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1066 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. McBane II, R. J. Leadley Jr, S. M. Baxi, K. Karnicki, and W. Wysokinski Iliac Venous Stenting: Antithrombotic Efficacy of PD0348292, an Oral Direct Factor Xa Inhibitor, Compared With Antiplatelet Agents in Pigs Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 413 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michelson P2Y12 Antagonism: Promises and Challenges Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Li, E. Yow, K. Y. Berezny, P. M. Bokesch, M. Takahashi, T. P. Graham Jr, S. P. Sanders, D. Sidi, D. Bonnet, P. Ewert, et al. Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial Circulation, January 29, 2008; 117(4): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gilard, B. Arnaud, J.-C. Cornily, G. Le Gal, K. Lacut, G. Le Calvez, J. Mansourati, D. Mottier, J.-F. Abgrall, and J. Boschat Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study J. Am. Coll. Cardiol., January 22, 2008; 51(3): 256 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, W. C. Lau, and U. S. Tantry Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel J. Am. Coll. Cardiol., January 22, 2008; 51(3): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gachet and B. Aleil Testing antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial Circulation, December 18, 2007; 116(25): 2923 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, S. Husted, R. A. Harrington, B. M. Scirica, H. Emanuelsson, G. Peters, R. F. Storey, and for the DISPERSE-2 Investigators Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1844 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Storey, S. Husted, R. A. Harrington, S. Heptinstall, R. G. Wilcox, G. Peters, M. Wickens, H. Emanuelsson, P. Gurbel, P. Grande, et al. Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1852 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1132 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Weerakkody, J. A. Jakubowski, J. T. Brandt, C. D. Payne, H. Naganuma, and K. J. Winters Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 205 - 212. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Payne, C. I. Jones, P. D. Hayes, A. R. Naylor, and A. H. Goodall Therapeutic Benefit of Low-Dose Clopidogrel in Patients Undergoing Carotid Surgery Is Linked to Variability in the Platelet Adenosine Diphosphate Response and Patients' Weight Stroke, September 1, 2007; 38(9): 2464 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Beckerath, A. Kastrati, A. Wieczorek, G. Pogatsa-Murray, D. Sibbing, I. Graf, and A. Schomig A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur. Heart J., August 1, 2007; 28(15): 1814 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eshaghian, S. Kaul, S. Amin, P. K. Shah, and G. A. Diamond Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease Ann Intern Med, March 20, 2007; 146(6): 434 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Bliden, J. DiChiara, U. S. Tantry, A. K. Bassi, S. K. Chaganti, and P. A. Gurbel Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? J. Am. Coll. Cardiol., February 13, 2007; 49(6): 657 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation, February 13, 2007; 115(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Kocabay, I Okcular, V Akkaya, and K. Guler Suicide attempt with clopidogrel Human and Experimental Toxicology, December 1, 2006; 25(12): 731 - 734. [Abstract] [PDF]
|
|
|
|
|
|
M. O'Donoghue and S. D. Wiviott Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? Circulation, November 28, 2006; 114(22): e600 - e606. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||